Sign in to view content

Loss to Follow-up in Patients With Proliferative Diabetic Retinopathy Treated With Anti-VEGF Therapy and/or PRP in the United States

Rahul N. Khurana, MD, FASRS

Video
Published 2021

Related

Retinal Nonperfusion on Widefield OCTA in Determining Diabetic Retinopathy Severity
Annual Meeting Talks
2023
Risk of Sight-Threatening Diabetic Retinopathy with GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes
Andrew J. Barkmeier, MD
Updates from the Field
2024
Evaluation of Nonperfusion Area and Other Vascular Metrics by Widefield SS-OCTA as Biomarkers of Diabetic Retinopathy Severity
John B. Miller, MD
Annual Meeting Talks
2021

Category: Diabetic Retinopathy

See more